Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.

Launched by CHINESE UNIVERSITY OF HONG KONG · Feb 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new test called the Direct Leukocyte Single cell-type Transcript Abundance (DIRECT LS-TA) assay. The goal of this test is to quickly determine whether a patient with a fever has a viral infection, a bacterial infection, or active tuberculosis by analyzing specific types of white blood cells in their blood. This approach focuses on how the body responds to infections rather than just looking for the germs themselves, which could help doctors provide the right treatment more quickly.

To be eligible for this trial, participants must be adults who have a fever that has started suddenly and be able to understand Chinese to give their consent. However, individuals with weakened immune systems or those who have recently received treatments that lower immunity will not be included. If you join the study, you can expect to have a blood sample taken, and the results will help researchers understand how this new test performs in identifying different types of infections. This could potentially lead to better care for patients with fever in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with fever of acute onset which is defined by a raised body temperature.
• • Patient should understand Chinese word to give informed consent.
• Exclusion Criteria:
• • Patients with a history of any immunodeficiency or immunocompromised condition. Patients received steriod or other immunotherapy.